Psoriatic arthritis and ankylosing spondylitis are the most common entities in a family of inflammatory rheumatologic diseases – seronegative spondyloarthropathies. Enteropathic arthritis, reactive arthritis and undifferentiated spondyloarthritis are also a part of seronegative spondyloarthropathies. They are different from other seropositive rheumatic diseases, such as rheumatoid arthritis, for their lack of antibodies and a broad spectrum of symptoms. Disease frequency varies in different population groups and is usually linked to human leukocyte antigen HLA-B27 presence in genome. Diagnosis and treatment cannot be performed uniformously in seronegative spondyloarthropathies. New treatment guidelines are formed due to advances in diagnostic technology and new knowledge on pathogenesis. Administration of newer drugs occurs more often using adequate indications even before classic therapy treatment becomes inefficient. Interleukin 17 (IL-17) inhibitors are a new treatment option for spondyloarthropathies. They are a part of biological drugs – their origin is biologic and they suppress immune system selectively. Although nonsteroidal anti-inflammatory and diesase-modifying anti-rheumatic drugs are the most often used pharmacological treatment, in the 21st Century biological drug administration finds its meaning as a treatment option. This paper is a review of the most common spondyloarthropathies, treatment complexity and interleukin 17 inhibitors possible treatment role.